Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy

Journal of the American Academy of Dermatology

Volumn 35, Issue 6, 1996, Pages 935-945

  Zic, John A ^a   Stricklin, George P ^a   Greer, John P ^a   Kinney, Marsha C ^a   Shyr, Yu ^a   Wilson, David C ^b,c   King Jr , Lloyd E ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; METHOTREXATE; METHOXSALEN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUVA; SKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 0029770034     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90118-8     Document Type: Article

References (50)

1. Berger CL, Warburton D, Raafat J, et al. Cutaneous T-cell lymphoma: neoplasm of T cells with helper activity. Blood 1979;53:642-51.
2. Nasu K, Said J, Vonderheid E, et al. Immunopathology of cutaneous T-cell lymphomas. Am J Pathol 1985;119:436-47.
3. Zackheim HS. Treatment of cutaneous T-cell lymphoma. Semin Dermatol 1994;13:207-15.
4. Herrmann JJ, Kuzel TM, Rosen ST, et al. Proceedings of the Second International Symposium on Cutaneous T-cell Lymphoma. J Am Acad Dermatol 1994;31:819-22.
5. Bunn PA, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994;121:592-602.
6. Herrmann JJ, Roenigk HH Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995;33:234-42.
7. Zackheim HS, Epstein EH Jr, McNutt NS, et al. Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. J Am Acad Dermatol 1983;9:363-74.
8. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989;20:416-28.
9. Grozea PN, Jones SE, McKelvey EM, et al. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep 1979;61:279-82.
10. Minna JD, Roenigk HH Jr, Glastein E. Report of the Committee of Therapy for Mycosis Fungoides and Sézary Syndrome. Cancer Treat Rep 1979;61:279-82.
11. Bunn PA Jr, Fischmann AB, Schechter GP, et al. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T cell lymphoma. Cancer Treat Rep 1979;63:713-7.
12. Winkler CF, Sausville EA, Ihde DC, et al. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. J Clin Oncol 1986;4:1094-100.
13. Braverman JM, Yager NB, Chen M, et al. Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol 1987;16:45-60.
14. Kaye F, Bunn P, Steinberg S, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
15. Bunn PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979;63:725-7.
16. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.
17. Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995;13:257-63.
18. Stadler R, Otte HG. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy. Recent Results Cancer Res 1995;139:392-401.
19. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316:297-303.
20. Edelson RL. Photopheresis: a new therapeutic concept. Yale J Biol Med 1989;62:565-77.
21. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992;27:427-33.
22. Lamberg SI, Green SB, Byar DP, et al. Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group. Cancer Treat Rep 1979;63:701-11.
23. Green SB, Byar DP, Lamberg SI. Prognostic variables in mycosis fungoides. Cancer 1981;47:2671-7.
24. Zic J, Arzubiaga C, Salhany KE, et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1992;27:729-36.
25. Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T-cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol 1988;132:255-77.
26. Borowitz MJ, Croker BP, Burchette J. Immunocytochemical detection of lymphocyte surface antigens in fixed tissue sections. J Histochem Cytochem 1982;30:171-4.
27. Pinkus GS, Thomas P, Said JW. Leu-M1 - a marker for Reed-Sternberg cells in Hodgkin's disease: an immunoperoxidase study of paraffin-embedded tissues. Am J Pathol 1985;119:244-52.
28. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
30. Armus S, Keyes B, Cahill C, et al. Photopheresis for the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1990;23:898-902.
31. Rook AH, Wolfe JT. Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. J Clin Apheresis 1994;9:28-30.
32. Wolfe JT, Lessin SR, Singh AH, et al. Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. Artif Organs 1994;18:888-97.
33. Hoppe RT, Cox RS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep 1979;63:691-700.
34. Tadros AAM, Tepperman BS, Hryniuk WM, et al. Total skin electron irradiation for mycosis fungoides: failure analysis and prognostic factors. Int J Radiat Oncol Biol Phys 1983;9:1279-87.
35. Hönigsmann H, Brenner W, Rauschmeier W, et al. Photochemotherapy for cutaneous T cell lymphoma. J Am Acad Dermatol 1984;10:238-45.
36. Koh HK. Is cutaneous T-cell lymphoma curable? Arch Dermatol 1995;131:1081-2.
37. Wilson LD, Licata AL, Braverman DVI, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995;32:987-95.
38. Heald PW, Perez MI, Christensen I, et al. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale J Biol Med 1989;62: 629-38.
39. Knobler RM. Photopheresis-extracorporeal irradiation of 8-MOP containing blood: a new therapeutic modality. Blut 1987;54:247-50.
40. Heald PW, Edelson RL. Photopheresis therapy of cutaneous T cell lymphoma. Keio J Med 1988;37:155-67.
41. Edelson RL. Photopheresis. J Clin Apheresis 1990;5:77-9.
42. Kim YH, Bishop K, Varghese A, et al. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995;131:1003-8.
43. Greer JP, Salhany KE, Cousar JB, et al. Clinical features associated with transformation of cerebriform T-cell lymphoma to a large cell process. Hematol Oncol 1990;8: 215-27.
44. Braverman IM. Transformation in cutaneous T-cell lymphoma. J Invest Dermatol 1993;101:249-50.
45. Schechter GP, Sausville EA, Fischmann AB. Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. Blood 1987;69:841-9.
46. Catterall MD, Addis BJ, Smith JL, et al. Sézary syndrome: transformation to a high grade T-cell lymphoma after treatment with cyclosporin A. Clin Exp Dermatol 1983;8:159-69.
47. Vonderheid EC, Bigler RD, Greenberg AS. Extracorporeal photopheresis and recombinant interferon alpha 2b in Sézary syndrome. Am J Clin Oncol 1994;17:255-63.
48. Rook AH, Prystowsky MB, Cassin M, et al. Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Arch Dermatol 1991;127:1535-40.
49. Lim HW, Harris HR. Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T-cell lymphoma undergoing photopheresis. Dermatol Surg 1995;21:597-9.
50. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Ann Int Med 1988;109:372-82.